The day in pharma, read in minutes.
NewsHikma Pharmaceuticals Appoints Ex-Cipla CEO Umang Vohra to Board
Hikma Pharmaceuticals names former Cipla CEO Umang Vohra to its Board and Audit Committee.
IDEAYA Biosciences Aligns with FDA on IDE849 Trial Strategy

FDA Approves Giredestrant Plus Everolimus for Breast Cancer

Cue Biopharma Reports Phase 2 CSU Data and CUE-401 Dosing

Mankind Pharma Secures Exclusive India Rights for Ensartinib

Latest news
11 storiesLantheus Meets Phase 3 Endpoints for TAUKLARIFY PET
Lantheus presents Phase 3 data for TAUKLARIFY tau-PET agent, meeting all sensitivity and specificity endpoints across 617 scans in early Alzheimer's disease.

UCB Gains FDA Approval for Klygefa as First Dual-Binding Nanobody C5 Inhibitor
UCB's Klygefa becomes the first dual-binding nanobody C5 inhibitor approved in the US for generalized myasthenia gravis, delivered via subcutaneous autoinjector.

Novartis Gains Positive CHMP Opinion for Cosentyx in Adolescents
Novartis's Cosentyx receives CHMP positive opinion for adolescent HS, triggering label expansion obligations across batch release, packaging, and pharmacovigilance in Europe.

Evotec Secures $2.9M Grant for Stem Cell Fetal Safety
Evotec receives a $2.9M Gates Foundation grant to extend its hiPSC-based fetal safety screening platform for global health drug programs.

EMA CHMP Recommends Seven Medicines at November 2026 Meeting
CHMP recommends seven new medicines at November 2026 meeting, including two insulin aspart biosimilars and generic ruxolitinib, advancing EU market entry timelines.

Reviva Secures USPTO Track 1 Review for Brilaroxazine
Reviva Pharmaceuticals gains USPTO Track 1 priority examination for a new brilaroxazine formulation patent, with exclusivity potentially extending to 2046.

Sutro Biopharma Advances Three ADC Programs Toward Clinic
Sutro Biopharma advances three site-specific ADC programs toward or into Phase 1, with cell-free conjugation enabling precise DAR control across dual-payload formats.

Immix Biopharma Appoints Dual SVPs Ahead of NXC-201 BLA
Immix Biopharma builds out CMC and regulatory leadership ahead of a mid-2027 NXC-201 BLA submission, with 89% complete response rate data heading to ASH.

Codexis Achieves 100-Gram Oligonucleotide Scale-Up
Codexis scales ECO Synthesis to 100g oligonucleotide output and targets GMP facility readiness by end of 2027 for early clinical siRNA supply.

Eros Apothecary Recalls Honey Supplement Over Tadalafil
Eros Apothecary recalls honey supplement after FDA lab testing detects undeclared tadalafil, flagging e-commerce supply chain oversight gaps.

Artelo Reports 40% Weight Loss with Semaglutide in Mice
Artelo's ART27.13 achieves ~40% weight loss combined with semaglutide in nonclinical model; U.S. patent protection expected through 2041.

Worth your time this week

Grace Therapeutics Advances Dual-Source CMO Strategy

Monopar Therapeutics Nears Rolling NDA Completion for ALXN1840

Kiora Pharmaceuticals Advances KIO-401 IND Pathway
